Clinical Commander

Back to dossier
cardio.dvt.thromboangiitis-obliterans.v1PRODUCTION
cardio.dvt.thromboangiitis-obliterans.v1

DVT/VTE in thromboangiitis obliterans (Buerger's disease)

cardiologyacuteadult
Hard-required inputs
0 / 12
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Buerger vascular phenotype: non-atherosclerotic segmental panvasculitis of small/medium arteries AND veins of the extremities; SMOKING CESSATION is the single most effective intervention — anticoagulation alone cannot halt the underlying inflammatory thrombo-occlusive process while tobacco exposure continues (Olin NEJM 2000 PMID 10995864; Cooper JACC 2004 PMID 14736464)

Inputs
1
Actions
0
Advance rule
Set
Advance when

Buerger pathophysiology framed

Patient inputs (12)

Shionoya criteria + Olin require exclusion of other vasculitides (ANCA-associated, Behçet, polyarteritis nodosa, GCA), thrombophilia, and autoimmune disease before Buerger diagnosis

CTA/MRA/conventional angiography to identify Buerger-specific findings (corkscrew collaterals, segmental occlusions sparing proximal vessels, no atheroma) supporting diagnosis (Olin NEJM 2000)

ANCA, ANA, anti-dsDNA, RF, anti-CCP, complement, cryoglobulins, antiphospholipid panel, factor V Leiden, prothrombin G20210A, protein C/S, antithrombin — required to exclude alternative diagnoses per Shionoya/Olin

Buerger typically <45 yr at onset; older onset prompts re-evaluation for atherosclerotic disease + other vasculitides (Shionoya criteria)

Historically M:F 100:1; rising female incidence with female smoking patterns; informs but does not exclude diagnosis

Pack-year quantification and current smoking status is THE defining etiologic + therapeutic variable — smoking cessation is the definitive intervention (Olin NEJM 2000 PMID 10995864; Cooper JACC 2004 PMID 14736464)

Shionoya criteria require absence of atherosclerotic risk factors (DM, HTN, hyperlipidemia, advanced age) — screen for and document these to support diagnosis

Cardinal symptom of DVT or distal ischemia in Buerger

Initial confirmation of DVT location (proximal vs distal vs small-vessel); Buerger typically affects distal segmental small/medium vessels

Baseline platelet for AC initiation; monitoring during therapy

HAS-BLED + falls + GI bleed + ulcer/wound care complications inform AC intensity and duration decisions

eGFR for DOAC dosing + iloprost dose adjustment if used

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningcritical_limb_ischemia_with_amputation_decision
    Buerger patient with rest pain, digital ulceration, gangrene, or impending tissue loss → critical limb ischemia requiring iloprost + amputation decision; bypass surgery rarely feasible due to small-vessel disease (Olin NEJM 2000 PMID 10995864)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecontinued_smoking_despite_intervention
    Patient continues active tobacco use despite cessation pharmacotherapy + behavioral support — single strongest predictor of disease progression and amputation in Buerger (Cooper JACC 2004 PMID 14736464)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereiloprost_induced_hypotension_or_intolerance
    During iloprost IV infusion for severe limb ischemia, patient develops hypotension, headache, flushing, or other prostacyclin-related side effects requiring dose reduction or discontinuation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereatypical_presentation_suggesting_other_vasculitis_or_thrombophilia
    Patient presenting as Buerger but with atypical features (proximal large-vessel involvement, ANCA positive, antiphospholipid positive, age >50, no smoking history, atherosclerotic risk factors present) → reconsider diagnosis; route to alternative vasculitis or thrombophilia engine
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_dvt_on_anticoagulation_with_continued_smoking
    Buerger patient with recurrent DVT despite therapeutic AC and continued tobacco use — vasculitic vessel-wall inflammation continues to drive thrombus formation; smoking cessation is the definitive fix, NOT AC escalation
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

ENTRYrequiredDrives risk stratification
Loading…

Recommended regimen

Buerger's disease VTE — ABSOLUTE smoking cessation + anticoagulation + iloprost for severe ischemia + wound care (Olin NEJM 2000 PMID 10995864; Cooper JACC 2004 PMID 14736464; Fiessinger Lancet 1990 PMID 1972973)
axis: buerger_disease_smoking_cessation_plus_anticoagulation_plus_ischemia_therapy
Selected axis "Buerger's disease VTE — ABSOLUTE smoking cessation + anticoagulation + iloprost for severe ischemia + wound care (Olin NEJM 2000 PMID 10995864; Cooper JACC 2004 PMID 14736464; Fiessinger Lancet 1990 PMID 1972973)" by default fallback (first axis)
  • apixaban
    first line
    doac_factor_xa_direct
    10 mg BID × 7 d → 5 mg BID • PO • BID for ≥3 mo; reassess based on smoking cessation + recurrence risk
    triggers: buerger_dvt_or_vte, no_active_bleed, egfr_above_25
    AMPLIFY (Agnelli NEJM 2013 PMID 23808982); ACCP 2021 (Stevens PMID 34352295); reasonable for Buerger-associated DVT but does NOT address underlying inflammatory vasculopathy — smoking cessation remains primary
    rxcui 1364430
  • rivaroxaban
    first line
    doac_factor_xa_direct
    15 mg BID × 21 d → 20 mg daily • PO • BID then daily for ≥3 mo
    triggers: buerger_dvt_or_vte, doac_alternative, egfr_above_30
    EINSTEIN-DVT (Bauersachs NEJM 2010 PMID 21128814)
    rxcui 1114195
  • enoxaparin
    first line
    lmwh
    1 mg/kg SC BID; reduce to 1 mg/kg daily if CrCl <30 • SC • BID
    triggers: inpatient_acute_bridge, doac_contraindicated
    ASH 2020 (PMID 33007077); ACCP 2021 — bridge for inpatient stabilisation
    rxcui 67108
  • warfarin
    second line
    vitamin_k_antagonist
    5 mg daily; INR target 2-3 • PO • daily
    triggers: doac_unaffordable, frequent_procedural_interruptions_for_wound_care_or_amputation
    Easier reversibility for procedural interruptions in wound care + amputation contexts
    rxcui 11289
  • varenicline
    first line
    partial_nicotinic_receptor_agonist
    0.5 mg PO daily × 3 d → 0.5 mg BID × 4 d → 1 mg BID × 12 wk minimum • PO • BID
    triggers: active_smoker_with_buerger_disease
    USPSTF + ACC/AHA tobacco cessation — most effective single agent for cessation; combined with behavioral support; smoking cessation is THE definitive Buerger intervention (Olin NEJM 2000; Cooper JACC 2004)
    rxcui 591622
  • nicotine
    first line
    nicotine_replacement_therapy
    patch 21 mg daily + lozenge/gum prn cravings • transdermal + PO • daily + prn
    triggers: active_smoker_with_buerger_disease, varenicline_contraindicated_or_intolerant
    NRT helps achieve cessation; nicotine itself is debated in Buerger but cessation outweighs nicotine concern when adjunctive to behavioral cessation
    rxcui 7407
  • bupropion
    add on
    atypical_antidepressant_smoking_cessation
    150 mg daily × 3 d → 150 mg BID × 12 wk • PO • BID
    triggers: adjunct_smoking_cessation, depression_comorbidity
    USPSTF — combined with NRT for additive cessation efficacy
    rxcui 42347
  • iloprost
    first line
    prostacyclin_analog
    0.5-2 ng/kg/min IV titrate × 6 hr daily for 2-4 wk • IV • daily × 2-4 wk
    triggers: severe_limb_ischemia_with_rest_pain_or_ulceration_in_buerger
    Fiessinger Lancet 1990 PMID 1972973 — placebo-RCT — iloprost superior to aspirin for ulcer healing + rest pain in Buerger; standard of care for severe ischemia per Olin NEJM 2000
    rxcui 40138
  • pentoxifylline
    second line
    methylxanthine_hemorheologic
    400 mg PO TID with meals • PO • TID
    triggers: adjunctive_for_claudication_or_limb_ischemia
    Limited evidence in Buerger but used; may improve microcirculation
    rxcui 8013
  • clopidogrel
    second line
    p2y12_inhibitor
    75 mg PO daily • PO • daily
    triggers: adjunctive_antiplatelet_for_ischemia
    Debated in Buerger; sometimes used alongside AC for severe ischemia (combined antithrombotic risk acknowledged)
    rxcui 32968
  • acetaminophen
    first line
    analgesic_anilide
    650-1000 mg PO q6h scheduled • PO • q6h
    triggers: ischemic_pain_or_post_procedural_pain
    Avoid NSAIDs due to bleed risk on AC; non-opioid baseline
    rxcui 161
  • gabapentin
    add on
    anticonvulsant_neuropathic
    300 mg PO TID titrate to 1800-3600 mg/day in divided doses • PO • TID
    triggers: neuropathic_ischemic_pain
    Neuropathic pain component in chronic ischemia + post-amputation phantom pain
    rxcui 25480
  • morphine
    rescue
    opioid_analgesic
    2-4 mg IV q4h prn breakthrough pain • IV • q4h prn
    triggers: severe_ischemic_pain_inadequately_controlled_by_acetaminophen_gabapentin
    Severe ischemic pain in critical limb ischemia or post-amputation; multidisciplinary pain control + chronic pain consult if prolonged
    rxcui 7052

outpatient playbook — drug actions (4)

  1. 1. maintenance apixaban (duration tied to recurrence risk + smoking cessation)
    rxcui 1364430
    apixaban 5 mg BID OR 2.5 mg BID extended-reduced after first 6 mo if continuing indefinite • PO • BID
    trigger: Indefinite if recurrence risk persists or smoking continues
    AMPLIFY-EXT (Agnelli NEJM 2013 PMID 23216615); ACCP 2021
  2. 2. continue varenicline as long as needed for sustained cessation
    rxcui 1551291
    varenicline 1 mg BID × 6-12 mo or longer if needed • PO • BID
    trigger: Active or recently active smoking
    USPSTF — sustained pharmacotherapy improves long-term abstinence
  3. 3. wean NRT per cessation success
    rxcui 7456
    nicotine patch 21 mg → 14 mg → 7 mg taper over months • transdermal • daily tapering
    trigger: Sustained cessation
    Standard NRT taper protocol
  4. 4. chronic pain regimen per pain consult
    rxcui 3423
    gabapentin + acetaminophen + opioid as needed per chronic pain consult • PO • as scheduled
    trigger: Chronic ischemic or post-amputation pain
    CDC opioid guideline + multimodal

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: DVT or migratory superficial thrombophlebitis in young (<45) heavy smoker without atherosclerotic risk factors → Buerger workup (Olin NEJM 2000 PMID 10995864; Shionoya 1989 PMID 9568200); Distal extremity rest pain, digital ulceration, gangrene + concurrent VTE in young smoker → Buerger arterial-venous overlap pathway; Recurrent DVT in patient with ongoing tobacco use + no atherosclerotic risk factors + segmental small-vessel involvement → consider Buerger.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**DVT/VTE in thromboangiitis obliterans (Buerger's disease)** (cardio.dvt.thromboangiitis-obliterans.v1).
Scope: Buerger vascular phenotype: non-atherosclerotic segmental panvasculitis of small/medium arteries AND veins of the extremities; SMOKING CESSATION is the single most effective intervention — anticoagulation alone cannot halt the underlying inflammatory thrombo-occlusive process while tobacco exposure continues (Olin NEJM 2000 PMID 10995864; Cooper JACC 2004 PMID 14736464)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Buerger's disease VTE — ABSOLUTE smoking cessation + anticoagulation + iloprost for severe ischemia + wound care (Olin NEJM 2000 PMID 10995864; Cooper JACC 2004 PMID 14736464; Fiessinger Lancet 1990 PMID 1972973)**.
1. apixaban 10 mg BID × 7 d → 5 mg BID PO BID for ≥3 mo; reassess based on smoking cessation + recurrence risk (doac_factor_xa_direct, first line) — AMPLIFY (Agnelli NEJM 2013 PMID 23808982); ACCP 2021 (Stevens PMID 34352295); reasonable for Buerger-associated DVT but does NOT address underlying inflammatory vasculopathy — smoking cessation remains primary
2. rivaroxaban 15 mg BID × 21 d → 20 mg daily PO BID then daily for ≥3 mo (doac_factor_xa_direct, first line) — EINSTEIN-DVT (Bauersachs NEJM 2010 PMID 21128814)
3. enoxaparin 1 mg/kg SC BID; reduce to 1 mg/kg daily if CrCl <30 SC BID (lmwh, first line) — ASH 2020 (PMID 33007077); ACCP 2021 — bridge for inpatient stabilisation
4. warfarin 5 mg daily; INR target 2-3 PO daily (vitamin_k_antagonist, second line) — Easier reversibility for procedural interruptions in wound care + amputation contexts
5. varenicline 0.5 mg PO daily × 3 d → 0.5 mg BID × 4 d → 1 mg BID × 12 wk minimum PO BID (partial_nicotinic_receptor_agonist, first line) — USPSTF + ACC/AHA tobacco cessation — most effective single agent for cessation; combined with behavioral support; smoking cessation is THE definitive Buerger intervention (Olin NEJM 2000; Cooper JACC 2004)
6. nicotine patch 21 mg daily + lozenge/gum prn cravings transdermal + PO daily + prn (nicotine_replacement_therapy, first line) — NRT helps achieve cessation; nicotine itself is debated in Buerger but cessation outweighs nicotine concern when adjunctive to behavioral cessation
7. bupropion 150 mg daily × 3 d → 150 mg BID × 12 wk PO BID (atypical_antidepressant_smoking_cessation, add on) — USPSTF — combined with NRT for additive cessation efficacy
8. iloprost 0.5-2 ng/kg/min IV titrate × 6 hr daily for 2-4 wk IV daily × 2-4 wk (prostacyclin_analog, first line) — Fiessinger Lancet 1990 PMID 1972973 — placebo-RCT — iloprost superior to aspirin for ulcer healing + rest pain in Buerger; standard of care for severe ischemia per Olin NEJM 2000
9. pentoxifylline 400 mg PO TID with meals PO TID (methylxanthine_hemorheologic, second line) — Limited evidence in Buerger but used; may improve microcirculation
10. clopidogrel 75 mg PO daily PO daily (p2y12_inhibitor, second line) — Debated in Buerger; sometimes used alongside AC for severe ischemia (combined antithrombotic risk acknowledged)
11. acetaminophen 650-1000 mg PO q6h scheduled PO q6h (analgesic_anilide, first line) — Avoid NSAIDs due to bleed risk on AC; non-opioid baseline
12. gabapentin 300 mg PO TID titrate to 1800-3600 mg/day in divided doses PO TID (anticonvulsant_neuropathic, add on) — Neuropathic pain component in chronic ischemia + post-amputation phantom pain
13. morphine 2-4 mg IV q4h prn breakthrough pain IV q4h prn (opioid_analgesic, rescue) — Severe ischemic pain in critical limb ischemia or post-amputation; multidisciplinary pain control + chronic pain consult if prolonged

Setting playbook (outpatient) — Long-term smoking cessation reinforcement (the single most important variable for long-term outcomes per Cooper JACC 2004); AC continuation tied to recurrence risk; vascular + wound + pain follow-up; amputation prevention or post-amputation rehab
14. maintenance apixaban (duration tied to recurrence risk + smoking cessation) apixaban 5 mg BID OR 2.5 mg BID extended-reduced after first 6 mo if continuing indefinite PO BID — Indefinite if recurrence risk persists or smoking continues (AMPLIFY-EXT (Agnelli NEJM 2013 PMID 23216615); ACCP 2021)
15. continue varenicline as long as needed for sustained cessation varenicline 1 mg BID × 6-12 mo or longer if needed PO BID — Active or recently active smoking (USPSTF — sustained pharmacotherapy improves long-term abstinence)
16. wean NRT per cessation success nicotine patch 21 mg → 14 mg → 7 mg taper over months transdermal daily tapering — Sustained cessation (Standard NRT taper protocol)
17. chronic pain regimen per pain consult gabapentin + acetaminophen + opioid as needed per chronic pain consult PO as scheduled — Chronic ischemic or post-amputation pain (CDC opioid guideline + multimodal)

Non-pharmacologic actions:
- Smoking cessation behavioral support indefinite
- Quarterly multidisciplinary visits
- Patient + family education + support group referral
- Prosthetics + rehab if amputation
- Mental health support indefinite

AVOID / contraindication checks:
- Doac_avoid_active_bleeding (FDA labels)
- Doac_avoid_triple_positive_aps_use_warfarin (TRAPS 2018)
- Varenicline_neuropsychiatric_warning_screen_for_depression_suicidality (FDA black box)
- Bupropion_avoid_seizure_history_eating_disorder (drug label)
- Iloprost_dose_adjust_renal_or_hepatic_impairment_monitor_BP_for_hypotension (drug label)
- NSAIDs_AVOID_on_AC (bleed risk)
- Decision:smoking_cessation_is_THE_definitive_intervention_anticoagulation_alone_inadequate (Olin NEJM 2000; Cooper JACC 2004)
- Decision:bypass_surgery_rarely_feasible_due_to_small_vessel_distal_disease_no_acceptable_target (Olin NEJM 2000)
- Decision:amputation_common_if_continued_smoking_progressive_ulceration (Cooper JACC 2004)
- Decision:iloprost_first_line_for_severe_limb_ischemia_per_Fiessinger_RCT (Lancet 1990 PMID 1972973)
- Decision:multidisciplinary_care_vascular_surgery_pain_management_smoking_cessation_wound_care (ESVS 2017)
- Decision:AC_duration_at_least_3_mo_then_individualised_based_on_smoking_cessation_success_and_recurrence (ACCP 2021)

Monitoring

Regimen monitoring:
- smoking cessation status at every visit with quantitative pack per day log (USPSTF; Cooper JACC 2004)
- cotinine or exhaled CO for objective smoking verification if clinically indicated
- cbc creatinine LFT baseline then per AC protocol
- pts villalta at 3 6 12 months for post thrombotic syndrome (Kahn Lancet 2014)
- serial wound assessment with wound care team if ulceration present
- pain score at every visit with chronic pain consult if prolonged
- ankle brachial index segmental pressures toe pressures q3 6 mo for ischemia progression
- transcutaneous oxygen or microcirculation assessment per vascular lab
- multidisciplinary team handoffs vascular surgery pain management smoking cessation wound care psychiatry if depression
- annual AC continuation decision tied to smoking cessation success and recurrence risk (ACCP 2021)
- amputation outcomes tracking if amputation performed (Cooper JACC 2004)

Setting (outpatient) monitoring:
- Quarterly visits during active disease, q6 mo in remission with sustained cessation
- Annual HAS-BLED + AC continuation decision
- Annual ABI + toe pressures + ischemia progression
- PTS Villalta annually

Follow-up plan: Long-term smoking cessation reinforcement + vascular + rheumatology follow-up; AC continuation tied to recurrence risk + ongoing disease activity; complete cessation generally arrests progression and may reverse ischemia (Cooper 2004); continued smoking → amputation common
- Close-out criterion: multidisciplinary maintenance plan + smoking cessation support documented

Monitoring phase: Smoking cessation adherence (continued tobacco use is the single strongest predictor of disease progression and amputation per Cooper JACC 2004); CBC + BMP + bleed surveillance; serial wound + ischemia assessment; PTS Villalta at 3/6/12 mo; rheumatology + vascular surgery + ID follow-up if wound infection

Disposition

Current setting: outpatient — Long-term smoking cessation reinforcement (the single most important variable for long-term outcomes per Cooper JACC 2004); AC continuation tied to recurrence risk; vascular + wound + pain follow-up; amputation prevention or post-amputation rehab

Disposition criteria:
- Indefinite multidisciplinary follow-up; cessation success often arrests progression; consider AC taper after sustained remission ≥1-2 yr with confirmed smoking cessation; amputation rates are high in continued smokers per Cooper JACC 2004

Escalation triggers (move to higher acuity):
- Recurrence on AC + continued smoking → escalate cessation effort (intensify pharmacotherapy + behavioral + psychiatry); reassess AC duration
- New ischemia despite cessation → vascular surgery for revascularization assessment (rarely feasible due to small-vessel disease)
- Wound deterioration → wound care + ID + vascular surgery
- Major bleed → reverse, hold AC, reassess indefinite indication

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Buerger patient with rest pain, digital ulceration, gangrene, or impending tissue loss → critical limb ischemia requiring iloprost + amputation decision; bypass surgery rarely feasible due to small-vessel disease (Olin NEJM 2000 PMID 10995864)
- [SEVERE] Patient continues active tobacco use despite cessation pharmacotherapy + behavioral support — single strongest predictor of disease progression and amputation in Buerger (Cooper JACC 2004 PMID 14736464)
- [SEVERE] During iloprost IV infusion for severe limb ischemia, patient develops hypotension, headache, flushing, or other prostacyclin-related side effects requiring dose reduction or discontinuation

Citations

- Olin JW. Thromboangiitis obliterans (Buerger's disease). NEJM 2000 PMID 10995864 — definitive review anchoring diagnosis, smoking cessation as definitive intervention, and management framework. Cooper LT et al. JACC 2004 PMID 14736464 — long-term outcomes anchor (continued smoking → amputation). Shionoya 1989 PMID 9568200 — diagnostic criteria. Fiessinger Lancet 1990 PMID 1972973 — iloprost RCT for severe limb ischemia. Olin & Shih 2006 PMID 16344631 — Curr Opin Rheumatol management update. ESVS 2017 PAD guidelines + Buerger's subsection. ACR/Vasculitis Foundation 2021 vasculitis recommendations. ACCP/CHEST 2021 (Stevens PMID 34352295) for AC duration. ASH 2020 VTE Treatment (Ortel PMID 33007077) for DOAC choice. [PMID:10995864](https://pubmed.ncbi.nlm.nih.gov/10995864/)
- Cited evidence (PMID 14736464) [PMID:14736464](https://pubmed.ncbi.nlm.nih.gov/14736464/)
- Cited evidence (PMID 9568200) [PMID:9568200](https://pubmed.ncbi.nlm.nih.gov/9568200/)
- Cited evidence (PMID 1972973) [PMID:1972973](https://pubmed.ncbi.nlm.nih.gov/1972973/)
- Cited evidence (PMID 16344631) [PMID:16344631](https://pubmed.ncbi.nlm.nih.gov/16344631/)

Last reconciled with current guidelines: 2026-05-15.
References
  • Olin JW. Thromboangiitis obliterans (Buerger's disease). NEJM 2000 PMID 10995864 — definitive review anchoring diagnosis, smoking cessation as definitive intervention, and management framework. Cooper LT et al. JACC 2004 PMID 14736464 — long-term outcomes anchor (continued smoking → amputation). Shionoya 1989 PMID 9568200 — diagnostic criteria. Fiessinger Lancet 1990 PMID 1972973 — iloprost RCT for severe limb ischemia. Olin & Shih 2006 PMID 16344631 — Curr Opin Rheumatol management update. ESVS 2017 PAD guidelines + Buerger's subsection. ACR/Vasculitis Foundation 2021 vasculitis recommendations. ACCP/CHEST 2021 (Stevens PMID 34352295) for AC duration. ASH 2020 VTE Treatment (Ortel PMID 33007077) for DOAC choice. — PMID:10995864
  • Cited evidence (PMID 14736464) — PMID:14736464
  • Cited evidence (PMID 9568200) — PMID:9568200
  • Cited evidence (PMID 1972973) — PMID:1972973
  • Cited evidence (PMID 16344631) — PMID:16344631